Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc"R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. more
Time Frame | ITOS | Sector | S&P500 |
---|---|---|---|
1-Week Return | -12.53% | -3.39% | -3.47% |
1-Month Return | -7.87% | -3.25% | -0.29% |
3-Month Return | -37.36% | -11.61% | 4.5% |
6-Month Return | -51.44% | -5.89% | 6.91% |
1-Year Return | -32.09% | 2.65% | 23.79% |
3-Year Return | -83.25% | 0.56% | 28.43% |
5-Year Return | -61.89% | 34.63% | 83.64% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | 344.77M | 267.63M | 12.60M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":77.62,"profit":true},{"date":"2023-12-31","value":3.65,"profit":true}] |
Cost of Revenue | 611.00K | 535.00K | 615.00K | 813.00K | 898.00K | [{"date":"2019-12-31","value":68.04,"profit":true},{"date":"2020-12-31","value":59.58,"profit":true},{"date":"2021-12-31","value":68.49,"profit":true},{"date":"2022-12-31","value":90.53,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (611.00K) | (535.00K) | 344.16M | 266.82M | 11.70M | [{"date":"2019-12-31","value":-0.18,"profit":false},{"date":"2020-12-31","value":-0.16,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":77.53,"profit":true},{"date":"2023-12-31","value":3.4,"profit":true}] |
Gross Margin | - | - | 99.82% | 99.70% | 92.87% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.87,"profit":true},{"date":"2023-12-31","value":93.04,"profit":true}] |
Operating Expenses | 23.27M | 39.31M | 89.69M | 138.04M | 163.70M | [{"date":"2019-12-31","value":14.21,"profit":true},{"date":"2020-12-31","value":24.01,"profit":true},{"date":"2021-12-31","value":54.79,"profit":true},{"date":"2022-12-31","value":84.33,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (28.05M) | (45.24M) | 244.90M | 126.32M | (151.10M) | [{"date":"2019-12-31","value":-11.45,"profit":false},{"date":"2020-12-31","value":-18.47,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":51.58,"profit":true},{"date":"2023-12-31","value":-61.7,"profit":false}] |
Total Non-Operating Income/Expense | 5.71M | - | 11.64M | 33.77M | 72.97M | [{"date":"2019-12-31","value":7.83,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":15.95,"profit":true},{"date":"2022-12-31","value":46.28,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (22.34M) | (38.09M) | 256.46M | 148.74M | (109.03M) | [{"date":"2019-12-31","value":-8.71,"profit":false},{"date":"2020-12-31","value":-14.85,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":57.99,"profit":true},{"date":"2023-12-31","value":-42.51,"profit":false}] |
Income Taxes | 119.00K | (57.00K) | 41.94M | 52.08M | 3.61M | [{"date":"2019-12-31","value":0.23,"profit":true},{"date":"2020-12-31","value":-0.11,"profit":false},{"date":"2021-12-31","value":80.53,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":6.93,"profit":true}] |
Income After Taxes | (22.45M) | - | 214.52M | 96.65M | (112.64M) | [{"date":"2019-12-31","value":-10.47,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":45.05,"profit":true},{"date":"2023-12-31","value":-52.51,"profit":false}] |
Income From Continuous Operations | (22.45M) | (38.03M) | 214.52M | 96.65M | (61.64M) | [{"date":"2019-12-31","value":-10.47,"profit":false},{"date":"2020-12-31","value":-17.73,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":45.05,"profit":true},{"date":"2023-12-31","value":-28.73,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (22.45M) | (38.03M) | 214.52M | 96.65M | (112.64M) | [{"date":"2019-12-31","value":-10.47,"profit":false},{"date":"2020-12-31","value":-17.73,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":45.05,"profit":true},{"date":"2023-12-31","value":-52.51,"profit":false}] |
EPS (Diluted) | - | (30.82) | 5.61 | 2.56 | (3.15) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-549.29,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":45.63,"profit":true},{"date":"2023-12-31","value":-56.15,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ITOS | |
---|---|
Cash Ratio | 13.28 |
Current Ratio | 14.80 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ITOS | |
---|---|
ROA (LTM) | -13.04% |
ROE (LTM) | -19.72% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ITOS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.13 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.87 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ITOS | |
---|---|
Trailing PE | NM |
Forward PE | 12.56 |
P/S (TTM) | 8.03 |
P/B | 0.45 |
Price/FCF | NM |
EV/R | 1.26 |
EV/Ebitda | 0.50 |
Iteos Therapeutics Inc (ITOS) share price today is $7.225
Yes, Indians can buy shares of Iteos Therapeutics Inc (ITOS) on Vested. To buy Iteos Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ITOS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Iteos Therapeutics Inc (ITOS) via the Vested app. You can start investing in Iteos Therapeutics Inc (ITOS) with a minimum investment of $1.
You can invest in shares of Iteos Therapeutics Inc (ITOS) via Vested in three simple steps:
The 52-week high price of Iteos Therapeutics Inc (ITOS) is $18.75. The 52-week low price of Iteos Therapeutics Inc (ITOS) is $7.13.
The price-to-earnings (P/E) ratio of Iteos Therapeutics Inc (ITOS) is
The price-to-book (P/B) ratio of Iteos Therapeutics Inc (ITOS) is 0.45
The dividend yield of Iteos Therapeutics Inc (ITOS) is 0.00%
The market capitalization of Iteos Therapeutics Inc (ITOS) is $280.95M
The stock symbol (or ticker) of Iteos Therapeutics Inc is ITOS